Mauricio Catalá

Immunology and Microbiology · Life Sciences

9h-index957citations30works1.02yr avg
OpenAlex↗Google Scholar↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Immunotherapy and Immune Responses(14), Cancer Immunotherapy and Biomarkers(9), Lung Cancer Treatments and Mutations(8), Cancer Research and Treatments(7), Glycosylation and Glycoproteins Research(5)

Publications30 total

Multidisciplinary consensus on the management of patients with osteopenia and fracture risk in Spain
BMC Musculoskeletal Disorders·2025· 1 citedOpen Access
Assessment of non-classical lymphocyte populations in patients with advanced lung cancer treated with Biomodulina T following platinum-based chemotherapy
Exploration of Immunology·2024· 1 citedOpen Access
Supplementary Figure S1 from A Phase III Clinical Trial of the Epidermal Growth Factor Vaccine CIMAvax-EGF as Switch Maintenance Therapy in Advanced Non–Small Cell Lung Cancer Patients
2023Open Access
Supplementary Table 3 from A Phase III Clinical Trial of the Epidermal Growth Factor Vaccine CIMAvax-EGF as Switch Maintenance Therapy in Advanced Non–Small Cell Lung Cancer Patients
2023Open Access
Supplementary Figure S1 from A Phase III Clinical Trial of the Epidermal Growth Factor Vaccine CIMAvax-EGF as Switch Maintenance Therapy in Advanced Non–Small Cell Lung Cancer Patients
2023Open Access
Data from A Phase III Clinical Trial of the Epidermal Growth Factor Vaccine CIMAvax-EGF as Switch Maintenance Therapy in Advanced Non–Small Cell Lung Cancer Patients
2023Open Access
Supplementary Table 3 from A Phase III Clinical Trial of the Epidermal Growth Factor Vaccine CIMAvax-EGF as Switch Maintenance Therapy in Advanced Non–Small Cell Lung Cancer Patients
2023Open Access
Supplementary Table S2 from A Phase III Clinical Trial of the Epidermal Growth Factor Vaccine CIMAvax-EGF as Switch Maintenance Therapy in Advanced Non–Small Cell Lung Cancer Patients
2023Open Access
Supplementary Table S2 from A Phase III Clinical Trial of the Epidermal Growth Factor Vaccine CIMAvax-EGF as Switch Maintenance Therapy in Advanced Non–Small Cell Lung Cancer Patients
2023Open Access
Data from A Phase III Clinical Trial of the Epidermal Growth Factor Vaccine CIMAvax-EGF as Switch Maintenance Therapy in Advanced Non–Small Cell Lung Cancer Patients
2023Open Access
Thymic Polypeptide Fraction Biomodulina T Decreases Exhausted and Terminally Differentiated EMRA T Cells in Advanced Lung Cancer Patients Treated With Platinum-Based Chemotherapy
Frontiers in Oncology·2022· 9 citedOpen Access
Associations among cytokines, EGF and lymphocyte subpopulations in patients diagnosed with advanced lung cancer
Cancer Immunology Immunotherapy·2021· 18 citedOpen Access
A Phase III Clinical Trial of the Epidermal Growth Factor Vaccine CIMAvax-EGF as Switch Maintenance Therapy in Advanced Non–Small Cell Lung Cancer Patients
Clinical Cancer Research·2016· 163 cited
Radiotherapy plus nimotuzumab or placebo in the treatment of high grade glioma patients: results from a randomized, double blind trial
BMC Cancer·2013· 78 citedOpen Access
Radiotherapy plus the anti-EGFR mAb nimotuzumab or placebo for the treatment of high-grade glioma patients.
Journal of Clinical Oncology·2012· 4 cited
Seguridad de inmunoterapia con veneno de himenópteros en pauta agrupada: Perspectiva de enfermería
Anales del Sistema Sanitario de Navarra·2009· 3 citedOpen Access
802 POSTER Epidermal Growth Factor (EGF) based cancer vaccine for NSCLC: immunological evaluation and impact on the EGFR signal transduction cascade
European Journal of Cancer Supplements·2007
Treatment of high-grade glioma patients with the humanized anti-epidermal growth factor receptor (EGFR) antibody h-R3: Report from a phase I/II trial
Cancer Biology & Therapy·2006· 161 citedOpen Access
Vaccination with EGF active immunotherapy improves survival in advanced non small cell lung cancer (NSCLC) patients: Interim analysis of a randomized phase II trial
Journal of Clinical Oncology·2005· 5 cited
Treatment of high-grade astrocytic tumors with the humanized anti-EGF-R antibody h-R3 and radiotherapy
Journal of Clinical Oncology·2005· 5 cited
page 1 of 2Next →

Frequent Co-authors

Tania Crombet(24), Elia Neninger(16), Agustín Lage(14), Zaima Mazorra(13), Ana de la Torre(12), Patricia Lorenzo-Luaces(12), Pedro C. Rodríguez(9), Xitllaly Popa(9), Odeth Martínez(9), Silvia Mendoza(9), Eduardo Santiesteban(9), Tatiana Crespo(9), Rosa M. Amador(9), Ricardo Fleytas(9), Soraida C. Acosta(9), Yanine Otero(9), Gala N. Romero(9), Mireysi Cala(9), Lina Arzuaga(9), Loisel Vello(9)